

Amendment Tool

v1.2 11 Jun 2020

For office use

QC: No

Section 1: Project information

Short project title*:	RECOVERY Trial			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281712			
Sponsor amendment reference number*:	Substantial Amendment 12			
Sponsor amendment date* (enter as DD/MM/YY):	15 December 2020			
Summary of amendment including justification*:	We wish to allow children for whom no main (first) randomisation treatments are both available and suitable to be recruited and considered for second randomisation (tocilizumab vs control).			
Project type:	<input checked="" type="radio"/> Specific study <input type="radio"/> Research tissue bank <input type="radio"/> Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable?:	<input checked="" type="radio"/> NHS/HSC REC <input type="radio"/> Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment?	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the Combined Ways of Working (CWOW) pilot?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study receive Pharmacy Assurance?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve access to confidential patient information without consent OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve prisoners OR does the amendment introduce this?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
Did the study involve NHS/HSC organisations prior to this amendment?:	<input checked="" type="radio"/> Yes		<input type="radio"/> No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	<input type="radio"/> Yes		<input checked="" type="radio"/> No	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<input checked="" type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
Which nations had participating NHS/HSC organisations prior to this amendment?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Which nations will have participating NHS/HSC organisations after this amendment?	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>

Section 2: Summary of change(s)

What do you want to update?:	<input checked="" type="radio"/> Project information <input type="radio"/> New site/PI only
------------------------------	--

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the amendment tool as three separate changes. A list of all possible changes is available on the "Glossary of Changes" tab. To add another change, tick the "Add another change" box.

Change 1				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study design that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	We wish to allow investigators in countries outside UK to use up to 162 mg aspirin because 150 mg aspirin is not available routinely in some countries. This was modified in V11.2 of the protocol so it could be submitted to ECs outside the UK.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 2				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Other significant change to study design that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	We wish to allow children to be recruited into the trial cohort even if there are no treatments which are both available and suitable for them in the main randomisation. This frequently occurs for children with PIMS-TS who are treated by their doctors with steroids and intravenous immunoglobulin. This currently means they cannot then enter the second randomisation (tocilizumab vs control), so we wish to allow these children to be recruited (but not randomised in the main randomisation) so they can then be considered for the second randomisation.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 3				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor document change that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	We wish to clarify the colchicine dosing in the appendix for participants who should receive a lower dose.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 4				
Area of change (select)*:	Study Documents			

Specific change (select - only available when area of change is selected first)*:	Other minor document change that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	Changes to children's PIS/ICF to align it with current adult version (and changes to access to second randomisation outlined in change 1).			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 5				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor document change that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information (free text):	Clarification of language around consent by legal representative.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☒

Change 6				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Correction of typographical errors			
Further information (free text):				
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>
Will all participating NHS/HSC organisations be affected by this change, or only some?:	<input checked="" type="radio"/> All		<input type="radio"/> Some	

Add another change: ☐

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate	
<ul style="list-style-type: none"> I confirm that the Sponsor takes responsibility for the completed amendment tool I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf 	
Name [first name and surname]*:	Elaine Chick
Email address*:	ctrg@admin.ox.ac.uk

Lock for submission

Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a PDF copy of the completed amendment tool that can be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, refer to the "Submission Guidance" tab for further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies																	Category:	
	UK wide:						England and Wales:				Scotland:			Northern Ireland:					
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons		National coordinating function
Change 1:	N	N				N				N				N				N	N/A
Change 2:	Y	Y				Y				Y				Y				Y	C
Change 3:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 4:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 5:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 6:	N	N				N				N				N				N	N/A
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		
Overall Category:	C																		